MindMed Announces Chief Executive Officer Transition

NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”),…

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

NEW YORK, May 26, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine…

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

NEW YORK, May 24, 2021 /CNW/ — MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage…

MindMed Announces the Approval of Mescaline Study

BASEL, Switzerland, May 20, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic…

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

NEW YORK, May 18, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (“MindMed” or the…

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May…

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

NEW YORK, May 14, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NASDAQ: MNMD) (NEO: MMED)…

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

NEW YORK, May 13, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company…

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics

NEW YORK, May 5, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NASDAQ: MNMD) (NEO:…

MindMed To Commence Trading on Nasdaq

NEW YORK, April 23, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech…

MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment

Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships,…

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine…